Skip to main content

Cerebrovascular Accident

14
Pipeline Programs
21
Companies
24
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
3
1
5
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
250%
Monoclonal Antibody
250%
+ 27 programs with unclassified modality

On Market (1)

Approved therapies currently available

REOPROApproved
abciximab
Unknown Company
injection1994

Competitive Landscape

19 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
ticagrelor + ASAPhase 41 trial
Active Trials
NCT04962451Completed13,000Est. Oct 2019
ViiV Healthcare
ViiV HealthcareNC - Durham
4 programs
1
2
1
GSK1358820Phase 3
GSK249320 100/mgPhase 2
RopinirolePhase 2
GSK249320APhase 1
Human BioSciences
Human BioSciencesWV - Martinsburg
3 programs
1
Constraint-induced movement therapyPhase 31 trial
Fast Walking with Fast Functional Electrical StimulationN/A1 trial
Hand MentorN/A1 trial
Active Trials
NCT01668602Completed24Est. May 2019
NCT00435617Completed78Est. May 2010
NCT00057018Completed229Est. Jan 2006
Innovation Pharmaceuticals
2 programs
1
YouGrabber training device from YouRehab Ltd.Phase 31 trial
Electrically Assisted Movement TherapyN/A1 trial
Active Trials
NCT02563886Unknown12Est. Dec 2016
NCT01774669Completed54Est. Apr 2016
Prevail Therapeutics
2 programs
1
AbciximabPhase 3Monoclonal Antibody1 trial
atomoxetineN/A1 trial
Active Trials
NCT00634439Completed72,000Est. Sep 2008
NCT00073372Terminated808Est. Dec 2005
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
Magnesium SulfatePhase 31 trial
Active Trials
NCT00059332Completed1,700Est. Mar 2013
Ono Pharmaceutical
Ono PharmaceuticalJapan - Osaka
1 program
1
ONO-2506Phase 2/31 trial
Active Trials
NCT00046761Terminated1,320
Astellas
AstellasChina - Shenyang
1 program
1
YM872Phase 21 trial
Active Trials
NCT00044070CompletedEst. Jan 2003
Spine BioPharma
Spine BioPharmaNY - New York
1 program
1
Autologous bone marrow mononuclear cell transplantationPhase 11 trial
Active Trials
NCT02065778Withdrawn0Est. Jan 2014
Biocorp
BiocorpFrance - Issoire
1 program
1
Perfusion with New Combination MedicationPhase 11 trial
Active Trials
NCT03543917Completed17Est. Sep 2018
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
5 programs
HippotherapyN/A1 trial
Aggrenox capsulePHASE_31 trial
Aggrenox® modified release capsulesPHASE_31 trial
rt-PA 0.9 mg/kg verum or placebo IntravenousPHASE_31 trial
Aggrenox bidPHASE_41 trial
Active Trials
NCT04759326Recruiting52Est. Mar 2026
NCT00311402Completed1,295
NCT00274586Completed100Est. Apr 2003
+2 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
atomoxetineN/A
AbciximabPHASE_3Monoclonal Antibody
Wicab
WicabWI - Fitchburg
1 program
BrainPort Balance DeviceN/A1 trial
Active Trials
NCT00567944Completed29Est. Apr 2010
CENTOGENE
CENTOGENEGermany - Rostock
1 program
Fabry and Cardiomyopathy (FaCard)N/A1 trial
Active Trials
NCT01429597Withdrawn0Est. Dec 2019
Mission Therapeutics
Mission TherapeuticsUK - Cambridge
1 program
Focus of attentionN/A1 trial
Active Trials
NCT04696302Completed38Est. May 2019
Alliance Pharmaceuticals
1 program
HippotherapyN/A
Sandoz
SandozAustria - Kundl
1 program
ValsartanN/ASmall Molecule1 trial
Active Trials
NCT00627991Withdrawn0
Ipsen
IpsenChina - Tianjin
1 program
Botulinum toxin type APHASE_41 trial
Active Trials
NCT00216411Completed96Est. Jul 2006
Takeda
TakedaTOKYO, Japan
1 program
CandesartanPHASE_4Small Molecule1 trial
Active Trials
NCT00108706Unknown50Est. Sep 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaticagrelor + ASA
Boehringer IngelheimAggrenox bid
TakedaCandesartan
IpsenBotulinum toxin type A
Innovation PharmaceuticalsYouGrabber training device from YouRehab Ltd.
Boehringer IngelheimAggrenox capsule
Angeles TherapeuticsMagnesium Sulfate
Prevail TherapeuticsAbciximab
Boehringer Ingelheimrt-PA 0.9 mg/kg verum or placebo Intravenous
Boehringer IngelheimAggrenox® modified release capsules
Human BioSciencesConstraint-induced movement therapy
Ono PharmaceuticalONO-2506
AstellasYM872
BiocorpPerfusion with New Combination Medication
Spine BioPharmaAutologous bone marrow mononuclear cell transplantation

Showing 15 of 24 trials with date data

Clinical Trials (24)

Total enrollment: 92,274 patients across 24 trials

NCT04962451AstraZenecaticagrelor + ASA

Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke

Start: Sep 2017Est. completion: Oct 201913,000 patients
Phase 4Completed
NCT00562588Boehringer IngelheimAggrenox bid

EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA

Start: Jul 2007551 patients
Phase 4Completed
NCT00108706TakedaCandesartan

Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)

Start: Dec 2004Est. completion: Sep 200750 patients
Phase 4Unknown
NCT00216411IpsenBotulinum toxin type A

Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm

Start: Nov 2004Est. completion: Jul 200696 patients
Phase 4Completed
NCT01774669Innovation PharmaceuticalsYouGrabber training device from YouRehab Ltd.

Effectiveness Study on a Virtual Reality Based Training System for Stroke Patients

Start: Jan 2013Est. completion: Apr 201654 patients
Phase 3Completed
NCT00311402Boehringer IngelheimAggrenox capsule

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme

Start: Apr 20061,295 patients
Phase 3Completed
NCT00059332Angeles TherapeuticsMagnesium Sulfate

Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial

Start: Jan 2005Est. completion: Mar 20131,700 patients
Phase 3Completed
NCT00073372Prevail TherapeuticsAbciximab

A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)

Start: Oct 2003Est. completion: Dec 2005808 patients
Phase 3Terminated
NCT00153036Boehringer Ingelheimrt-PA 0.9 mg/kg verum or placebo Intravenous

Rt-PA in the Treatment of Acute Ischemic Stroke

Start: Apr 2003821 patients
Phase 3Completed
NCT00274586Boehringer IngelheimAggrenox® modified release capsules

Headache Study to Compare Aggrenox Full Dose and Reduced Dose

Start: Sep 2002Est. completion: Apr 2003100 patients
Phase 3Completed
NCT00057018Human BioSciencesConstraint-induced movement therapy

Improving Arm Mobility and Use After Stroke

Start: Apr 2000Est. completion: Jan 2006229 patients
Phase 3Completed
NCT00046761Ono PharmaceuticalONO-2506

A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke

Start: Nov 20021,320 patients
Phase 2/3Terminated
NCT00044070AstellasYM872

A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients

Start: Dec 2000Est. completion: Jan 2003
Phase 2Completed
NCT03543917BiocorpPerfusion with New Combination Medication

Post-Stroke Improvement of Motor Function

Start: Aug 2017Est. completion: Sep 201817 patients
Phase 1Completed
NCT02065778Spine BioPharmaAutologous bone marrow mononuclear cell transplantation

Safety and Efficacy of Autologous Stem Cell Therapy in Chronic Stroke

Start: Dec 2008Est. completion: Jan 20140
Phase 1Withdrawn
NCT04759326Boehringer IngelheimHippotherapy

Neurorehabilitation Through Hippotherapy of a Brain Stroke

Start: Apr 2022Est. completion: Mar 202652 patients
N/ARecruiting
NCT02563886Innovation PharmaceuticalsElectrically Assisted Movement Therapy

Electrically Assisted Movement Therapy

Start: Sep 2015Est. completion: Dec 201612 patients
N/AUnknown
NCT04696302Mission TherapeuticsFocus of attention

Focus of Attention in Individuals With Stroke

Start: Mar 2015Est. completion: May 201938 patients
N/ACompleted
NCT01668602Human BioSciencesFast Walking with Fast Functional Electrical Stimulation

Stroke Gait Rehabilitation Using Functional Electrical Stimulation

Start: Aug 2013Est. completion: May 201924 patients
N/ACompleted
NCT01429597CENTOGENEFabry and Cardiomyopathy (FaCard)

Fabry and Cardiomyopathy (FaCard)

Start: Jul 2011Est. completion: Dec 20190
N/AWithdrawn
NCT00634439Prevail Therapeuticsatomoxetine

Safety Study of Atomoxetine and Cerebrovascular Outcomes

Start: Jan 2008Est. completion: Sep 200872,000 patients
N/ACompleted
NCT00627991SandozValsartan

Blood Pressure Lowering in Acute Stroke Trial (BLAST)

Start: Aug 20070
N/AWithdrawn
NCT00567944WicabBrainPort Balance Device

Use of the BrainPort® Balance Device to Improve Balance in Adults With Balance Deficits Due to Stroke

Start: Jun 2007Est. completion: Apr 201029 patients
N/ACompleted
NCT00435617Human BioSciencesHand Mentor

Study of Hand Therapy 3 to 24 Months After Stroke

Start: May 2005Est. completion: May 201078 patients
N/ACompleted

Related Jobs

Sr Commercial Excellence Manager, Stroke

Imperative CareImperative Care
6d ago
$155K - $175K/yr

Sr Software Engineer, User Facing Applications

Imperative CareImperative Care
1w ago
$150K - $183K/yr

Staff Manufacturing Engineer, Consumables

Imperative CareImperative Care
1w ago
$150K - $170K/yr

Executive Associate II, Neuroscience GPLs

Bristol Myers SquibbBristol Myers Squibb
Cambridge - MA - US; Princeton Pike - NJ
2w ago
$82K - $99K/yr

Director, Program Management, Neuroscience

Bristol Myers SquibbBristol Myers Squibb
Princeton - NJ - US; Cambridge Crossing - MA - US
3w ago
$217K - $263K/yr

Senior Therapeutic Area Specialist, Neurology/MS – Orlando, FL

Bristol Myers SquibbBristol Myers Squibb
Orlando - FL - US
3w ago
$139K - $169K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 92,274 patients
21 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.